Update of VISION Trial Shows Continued Efficacy of Tepotinib in NSCLC

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Paul K. Paik, MD, a medical oncologist and clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the newest data from the VISION trial (NCT02864992) of tepotinib (Tepmetko) in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

After the newer data cutoff of July 2020 for cohort A of the VISION study, the investigators were able to evaluate updated, more longitudinal findings. Paik says that the data from this cohort held up in terms of consistency for the overall response rate (ORR), as well as the median progression-free survival (PFS). The ORR was 46% and the median PFS was 9 months with the study drug.

The investigators explored the demographic information in VISION and how the patient demographics relate to response to tepotinib, especially in terms of how many therapies patients had previously received. When compared with patients who were treatment naïve, those who had received prior therapy had similar results and the data were consistent for efficacy in the 2 groups. Patients who were previously treated immunotherapy, chemotherapy, or chemoimmunotherapy all had consistent efficacy data as well, with an ORR in the 40% range. The take home message of this newer data is that the efficacy stays consistent with further time and different demographics, according to Paik.